Search | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Displaying 2 results.

- Speech
Rituximab given after high dose therapy and autologous stem cell transplantation induces durable clearance of minimal residual disease in about half of the patients with follicular non Hodgkin's lymphoma: 36 months results of a multicenter open label phase II trial (M39012 trial).
Morschhauser, F. Recher, C. Milpied, N. Gressin, R Salles, G. Brice, P. Vey, N Haioun, C. Colombat, P Bourhis, JH Rossi, JF Berriot-Varoqueaux, N Bergougnoux, L Bosly, André[UCL] Delsol, G. Attal, M. (2004) 46th Annual Meeting of the American-Society-of-Hematology — San Diego(Ca)
- Speech
Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-Cell lymphoma (DLBCL) treated with R-CHOP 14 or RCHOP21: Preliminary results of the LNH03-6B randomized GELA study.
Delarue, R. Mounier, N. Haioun, C. Coiffier, B. Gisselbrecht, C. Ghesquieres, H. Lederlin, P. Blanc, M. Recher, C. Hermine, O. Reyes, F. Tilly, H. Bosly, André[UCL] (2006) 48th Annual Meeting of the American-Society-of-Hematology — Orlando(Fl)